NRx Pharmaceuticals, a clinical-stage biopharmaceutical company, plans to hold its 2023 Annual Meeting of Stockholders on December 19, 2023, in a virtual format. Key items on the agenda include the proposed election of Janet Rehnquist, a respected attorney with extensive experience in regulated industries like healthcare, to the company’s Board of Directors. Additionally, the management will discuss the planned spinoff of Hope Therapeutics, Inc., which focuses on IV Ketamine, expected to be owned initially by NRx Pharmaceuticals and its shareholders, along with new investors.
English 
German